[go: up one dir, main page]

NO20064603L - Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer. - Google Patents

Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer.

Info

Publication number
NO20064603L
NO20064603L NO20064603A NO20064603A NO20064603L NO 20064603 L NO20064603 L NO 20064603L NO 20064603 A NO20064603 A NO 20064603A NO 20064603 A NO20064603 A NO 20064603A NO 20064603 L NO20064603 L NO 20064603L
Authority
NO
Norway
Prior art keywords
antagonists
treatment
liver diseases
cbi receptor
preparations useful
Prior art date
Application number
NO20064603A
Other languages
English (en)
Inventor
Sophie Lotersztajn
Ariane Mallat
Pascale Grenard
Boris Julien
Jeanne Tran Van Nhieu
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20064603L publication Critical patent/NO20064603L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anvendelse av antagonister av CBI-reseptoren for fremstillingen av et preparat anvendelig for behandlingen av leversykdommer og fortrinnsvis for anvendelse av N-piperidino-5-(4-klorfenyl)-l-(2,4-diklorfenyl)-4- metylpyrazol-3-karboksamid.
NO20064603A 2004-03-09 2006-10-09 Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer. NO20064603L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290633A EP1574211A1 (en) 2004-03-09 2004-03-09 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
PCT/EP2005/003285 WO2005084652A2 (en) 2004-03-09 2005-03-08 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases

Publications (1)

Publication Number Publication Date
NO20064603L true NO20064603L (no) 2006-10-09

Family

ID=34814417

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064603A NO20064603L (no) 2004-03-09 2006-10-09 Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer.

Country Status (26)

Country Link
US (2) US8236763B2 (no)
EP (3) EP1574211A1 (no)
JP (1) JP2007527893A (no)
KR (1) KR20070026415A (no)
CN (1) CN1929828A (no)
AR (1) AR048087A1 (no)
AT (1) ATE520393T1 (no)
AU (1) AU2005218937B2 (no)
BR (1) BRPI0508560A (no)
CA (1) CA2557976A1 (no)
CY (1) CY1112078T1 (no)
DK (1) DK1725223T3 (no)
ES (1) ES2371552T3 (no)
IL (1) IL177465A0 (no)
MA (1) MA28454B1 (no)
MX (1) MXPA06010287A (no)
NO (1) NO20064603L (no)
PL (1) PL1725223T3 (no)
PT (1) PT1725223E (no)
RU (1) RU2402328C2 (no)
SI (1) SI1725223T1 (no)
TN (1) TNSN06272A1 (no)
TW (1) TWI337540B (no)
UA (1) UA94025C2 (no)
WO (1) WO2005084652A2 (no)
ZA (1) ZA200607159B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
US7875647B2 (en) 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
EA029400B1 (ru) * 2010-07-15 2018-03-30 Олег Ильич ЭПШТЕЙН Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
CA2889697C (en) * 2012-11-13 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
JP6598844B2 (ja) 2014-03-27 2019-10-30 バード・ロック・バイオ・インコーポレイテッド ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
CN106660968B (zh) 2014-05-09 2020-02-07 美国政府(由卫生和人类服务部的部长所代表) 吡唑衍生物及其作为大麻素受体介体的用途
JP2019502651A (ja) 2015-09-30 2019-01-31 バード・ロック・バイオ・インコーポレイテッドＢｉｒｄ Ｒｏｃｋ Ｂｉｏ， Ｉｎｃ． ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
WO2017184412A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
AT394493B (de) * 1989-05-11 1992-04-10 Homosan Ag Pharmazeutisches praeparat zur behandlung von lebererkrankungen
US5492891A (en) * 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US6143752A (en) * 1997-08-01 2000-11-07 Oren; Ran Method for preventing or arresting liver damage in humans
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2809621B1 (fr) 2000-05-12 2002-09-06 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
AU2001275127A1 (en) * 2000-06-01 2001-12-11 The Mclean Hospital Corporation Method for treating alcohol intoxication and alcohol abuse
US6632647B2 (en) * 2000-07-11 2003-10-14 Bayer Aktiengesellschaft Use of strains of parapoxvirus ovis against organ fibrosis
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
FR2837706A1 (fr) 2002-03-28 2003-10-03 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
CA2480856A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
WO2003086288A2 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US20040034968A1 (en) * 2002-06-14 2004-02-26 Hufcor, Inc. 360 Degree hinge and door closure apparatus
SE0202242D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Compounds
SE0202240D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Genes
CA2494091C (en) * 2002-08-02 2011-02-01 Richard B. Toupence Substituted furo [2,3-b| pyridine derivatives
FR2849032B1 (fr) * 2002-12-23 2006-04-28 Sanofi Synthelabo Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
CA2537535A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
RU2006117637A (ru) * 2003-10-24 2007-12-10 Зольвай Фармасьютиклз Гмбх (De) Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз
GB0403780D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
MXPA06010287A (es) 2007-02-14
PT1725223E (pt) 2011-12-02
IL177465A0 (en) 2007-07-04
US20120329833A1 (en) 2012-12-27
ZA200607159B (en) 2008-02-27
CN1929828A (zh) 2007-03-14
JP2007527893A (ja) 2007-10-04
RU2006134707A (ru) 2008-04-20
PL1725223T3 (pl) 2012-01-31
UA94025C2 (ru) 2011-04-11
CA2557976A1 (en) 2005-09-15
TNSN06272A1 (en) 2007-12-03
US8236763B2 (en) 2012-08-07
CY1112078T1 (el) 2015-11-04
WO2005084652A2 (en) 2005-09-15
HK1094674A1 (en) 2007-05-18
RU2402328C2 (ru) 2010-10-27
AU2005218937B2 (en) 2011-07-07
AU2005218937A1 (en) 2005-09-15
WO2005084652A3 (en) 2005-12-08
EP1725223A2 (en) 2006-11-29
SI1725223T1 (sl) 2012-01-31
ES2371552T3 (es) 2012-01-05
DK1725223T3 (da) 2011-11-28
EP2305220A2 (en) 2011-04-06
EP1574211A1 (en) 2005-09-14
US20080214449A1 (en) 2008-09-04
US8604060B2 (en) 2013-12-10
AR048087A1 (es) 2006-03-29
TW200534851A (en) 2005-11-01
MA28454B1 (fr) 2007-03-01
ATE520393T1 (de) 2011-09-15
EP2305220B1 (en) 2014-07-30
TWI337540B (en) 2011-02-21
BRPI0508560A (pt) 2007-08-14
KR20070026415A (ko) 2007-03-08
EP1725223B1 (en) 2011-08-17
EP2305220A3 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
CY1112078T1 (el) Χρηση των ανταγωνιστων του cb1 υποδοχεα για την παρασκευη ενος σκευασματος που θα χρησιμοποιηθει για τη θεραπεια των ηπατικων νοσων
NO20023765D0 (no) Anvendelse av sentrale cannabinoid-reseptorantagonister for fremstilling av medisiner utformet for å gjöre rökestans lettere
NO20033165D0 (no) (+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan, sammensetning og anvendelse derav
FR2849032B1 (fr) Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BR0214309A (pt) Derivados aril-1,4-pirazina substituìdos
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
DK1656346T3 (da) 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
IS2759B (is) CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi
NO20041879L (no) Polymorf form av rimonabant, fremgangsmate for fremstilling derav og farmasoytisk preparat inneholdende det samme.
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
ATE450508T1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
LU92238I2 (fr) 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one ou l'un de sls physiologiquement acceptables. autre formulation du composé chimiqu e:1-(4-Chlorophenyl)4-morpholino-imidazolin-2-one
MA28105A1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite
ATE478052T1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor- antagonisten zur behandlung von psychosen und neurologischen störungen
WO2003082256A3 (fr) Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1
IS2641B (is) 3-Fenýl setið pýridóindólón, framleiðsla og meðferðarleg notkun þess.
DK1828182T3 (da) Terapeutiske pyrazol[3,4-B]pyridiner og indazoler
ATE501134T1 (de) Indazole mit analgetischer aktivität
AU2003222435A8 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
NO20034738L (no) Fremgangsmåter og mellomprodukter for fremstilling av benzylperoksider
AR049475A1 (es) Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la bronquitis cronica, y de la bronconeumopatia cronica obstructiva
MA29263B1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
ES2328328A1 (es) Polimorfo alfa de una pirazolina sustituida, su preparacion y su uso como medicamento

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application